文献速递膀胱癌与上尿路尿路上皮癌

浆细胞样尿路上皮癌根治性膀胱切除术后的结局:明确改善局部肿瘤控制的必要性

Outcomes Following Radical Cystectomy for Plasmacytoid Urothelial Carcinoma: Defining the Need for Improved Local Cancer Control.
PubMed 文献 · Urology · 2016-11-16

研究纳入1980至2009年接受根治性膀胱切除术的46例浆细胞样尿路上皮癌与972例纯尿路上皮癌患者,病理标本由单一泌尿生殖病理学家复核。浆细胞样组更常见≥pT3期(83% vs 43%)和切缘阳性(31% vs 2.1%),总生存、癌特异生存和局部无复发生存均更差;按年龄、性别、体能状态、病理分期和淋巴结状态1:2匹配后,5年生存差异无统计学显著性。

要点

  • 浆细胞样尿路上皮癌根治性膀胱切除术后≥pT3期占83%、切缘阳性占31%。
  • 未匹配时浆细胞样组5年总生存27% vs 纯尿路上皮癌组45%(RR 1.4,P=.04)。
  • 匹配后5年总生存、癌特异生存及局部或远处无复发生存均无显著差异。

核心结论

  • 浆细胞样尿路上皮癌与根治性膀胱切除术后局部晚期疾病和切缘阳性的高发生率相关,并与局部复发率升高相关。
  • 需要进一步研究以明确辅助或新辅助治疗策略,改善这一罕见尿路上皮癌亚型的局部肿瘤控制。

研究设计与样本

  • 研究识别1980至2009年间接受根治性膀胱切除术的46例浆细胞样尿路上皮癌患者和972例纯尿路上皮癌患者。
  • 所有病理标本由单一泌尿生殖病理学家复核。
  • 按年龄、性别、东部肿瘤协作组体能状态、病理肿瘤分期和淋巴结状态,将浆细胞样尿路上皮癌患者与纯尿路上皮癌患者按1:2匹配。
  • 生存采用Kaplan-Meier法估计,并用log rank检验比较。

主要发现

  • 浆细胞样尿路上皮癌患者较纯尿路上皮癌患者更常见膀胱外疾病(≥pT3期):83% vs 43%(P<.0001)。
  • 浆细胞样尿路上皮癌患者较纯尿路上皮癌患者更常见切缘阳性:31% vs 2.1%(P<.0001)。
  • 浆细胞样尿路上皮癌与总生存降低相关:5年总生存27% vs 45%(RR 1.4,P=.04)。
  • 浆细胞样尿路上皮癌与癌特异生存降低相关:5年癌特异生存36% vs 57%(RR 1.7,P=.01)。
  • 浆细胞样尿路上皮癌与局部无复发生存降低相关:5年局部无复发生存63% vs 81%(RR 2,P=.01)。

关键数值与推荐

  • 浆细胞样尿路上皮癌患者与纯尿路上皮癌患者匹配后,5年总生存、癌特异生存及局部或远处无复发生存均无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate oncological outcomes after radical cystectomy (RC) in patients with plasmacytoid urothelial carcinoma (UC) and to compare survival to that in patients with pure UC of the bladder. MATERIALS AND METHODS: We identified 46 patients with plasmacytoid UC and 972 with pure UC who were treated with RC between 1980 and 2009. All pathologic specimens were re-reviewed by a single GU pathologist. Patients were matched 1:2 by age, gender, Eastern Cooperative Oncology Group performance status, pathologic tumor stage, and nodal status to patients with pure UC. Survival was estimated using the Kaplan-Meier method and compared with the log rank test. RESULTS: Patients with plasmacytoid UC were more likely to have extravesical disease (≥pT3) (83% vs 43%, P < .0001) and positive margins (31% vs 2.1%, P < .0001) than patients with pure UC. Plasmacytoid UC was associated with decreased overall survival (27% vs 45% at 5 years, relative risk [RR] 1.4, P = .04), cancer-specific survival (36% vs 57% at 5 years, RR 1.7, P = .01), and local recurrence-free survival (63% vs 81% at 5 years, RR 2, P = .01). When patients with plasmacytoid UC were matched to those with pure UC, there were no significant differences in 5-year overall, cancer-specific, and local or distant recurrence-free survival. CONCLUSION: Plasmacytoid UC is associated with a high rate of locally advanced disease and positive margins at RC, as well as increased local recurrence rates. Further research is necessary to delineate adjuvant or neoadjuvant treatment strategies to improve local cancer control of this rare subtype of UC.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Cockerill PA, Cheville JC, Boorjian SA, et al. Outcomes Following Radical Cystectomy for Plasmacytoid Urothelial Carcinoma: Defining the Need for Improved Local Cancer Control. Urology. 2016. PMID: 27865750. doi:10.1016/j.urology.2016.09.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。